Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: FDA considers emergency contraceptive label change, CRN points out FSMA exemptions; NAD refers Maxam claims to FTC

This article was originally published in The Tan Sheet

Executive Summary

FDA considers emergency contraceptive label change; CRN points out FSMA exemptions; NAD refers Maxam claims to FTC; P&G executives retire; nutritional product firms among top direct sellers; Boots recalls store brand products; more In Brief.

You may also be interested in...



Compliance Corner: Follow These 11 Steps To Prep For FDA Regulatory Meetings

Longtime industry expert Steve Niedelman offers manufacturers pointers so they’re not caught flatfooted during regulatory meetings with the US agency.

EMA Says Yes To Eight New Medicines, Holds Fire On Others

The European Medicines Agency today announced the new medicines it believes should be approved for use across the EU.

EU Thumbs Up Signals First-Ever Approval For Leo’s Tralokinumab

Leo’s moderate-to-severe atopic dermatitis drug is set to be approved for the first time worldwide.

Topics

Related Companies

UsernamePublicRestriction

Register

PS106734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel